Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000904 | 0.83 | TGFBR1 (0.39) | TGFBR1 | |
| SCHEMBL12745085 | 0.80 | — | — | |
| SCHEMBL14129240 | 0.78 | TSHR (0.43) | MLYCD | |
| SCHEMBL12745089 | 0.78 | ALDH1A1 (0.39) | MLYCD | |
| SCHEMBL10000902 | 0.76 | TGFBR1 (0.35) | TGFBR1 | |
| SCHEMBL905121 | 0.76 | TGFBR1 (0.36) | TGFBR1RXFP1 | |
| SCHEMBL10000908 | 0.76 | ALDH1A1 (0.39) | TGFBR1 | |
| SCHEMBL15132347 | 0.75 | MLYCD (0.31) | MLYCD | |
| SCHEMBL12745086 | 0.75 | ACACB (0.33) | MLYCD | |
| SCHEMBL15132236 | 0.74 | RIPK1 (0.35) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9171655-B2 | Solid electrolyte film, and method for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9171655-B2 | Solid electrolyte film, and method for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20120301811-A1 | Solid Electrolyte Film, and Method for Producing Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-11-29 | — | — | US | disclosed |
| WO-2012043619-A1 | ANTIBACTERIAL AGENT, SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME, ANTIBACTERIAL AGENT COMPOSITION, AND SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME | セントラル硝子株式会社 (JP) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | SEM1, CD81, VMA21 | TGFBR1 1915/4885RXFP1 3974/4885MLYCD 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.